| BRÁZDIL, Milan. Eslikarbazepin (Eslicarbazepine). Remedia. Praha, 2011, vol. 21, No 3, p. 238-243. ISSN 0862-8947. |
|
Other formats:
BibTeX
LaTeX
RIS
|
| Basic information | |
|---|---|
| Original name | Eslikarbazepin |
| Name (in English) | Eslicarbazepine |
| Authors | BRÁZDIL, Milan (203 Czech Republic, guarantor, belonging to the institution). |
| Edition | Remedia, Praha, 2011, 0862-8947. |
| Other information | |
|---|---|
| Original language | Czech |
| Type of outcome | Article in a journal |
| Field of Study | 30000 3. Medical and Health Sciences |
| Country of publisher | Czech Republic |
| Confidentiality degree | is not subject to a state or trade secret |
| RIV identification code | RIV/00216224:14740/11:00055580 |
| Organization unit | Central European Institute of Technology |
| Keywords in English | eslicarbazepine; epilepsy; add-on therapy |
| Tags | ok, rivok |
| Changed by | Changed by: Olga Křížová, učo 56639. Changed: 22/3/2012 23:59. |
| Abstract |
|---|
| Eslikarbazepin acetát (ESL) je nové antiepileptikum stabilizující napěťově řízený sodíkový kanál. Jeho doporučené dávkování v udržovací léčbě po titraci je 800-1200 mg/den podávaných v jedné denní dávce. |
| Abstract (in English) |
|---|
| Eslicarbazepine acetate (ESL)) is a novel antiepileptic drug that stabilizes the voltage-gated sodium channel. The recommended maintenance dosage after titration is 800-1200 mg given in a single daily dose. |
| Links | |
|---|---|
| MSM0021622404, plan (intention) | Name: Vnitřní organizace a neurobiologické mechanismy funkčních systémů CNS |
| Investor: Ministry of Education, Youth and Sports of the CR, The internal organisation and neurobiological mechanisms of functional CNS systems under normal and pathological conditions. | |
PrintDisplayed: 25/4/2024 10:31